PMCB Earnings PharmaCyte Biotech, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–22 of 22
| Q1 2027 | 2026-07-31 | -0.54 | 2026-09-14 | 10-Q |
| FY 2026 | 2026-04-30 | -2.77 | 2026-07-29 | 10-K |
| Q3 2026 | 2026-01-31 | -2.41 | 2026-03-17 | 10-Q |
| Q2 2026 | 2025-10-31 | -2.47 | 2025-12-18 | 10-Q |
| Q1 2027 | 2025-07-31 | -1.23 | 2026-09-14 | 10-Q |
| FY 2026 | 2025-04-30 | 3.19 | 2026-07-29 | 10-K |
| Q3 2026 | 2025-01-31 | 1.67 | 2026-03-17 | 10-Q |
| Q2 2026 | 2024-10-31 | 1.83 | 2025-12-18 | 10-Q |
| Q1 2026 | 2024-07-31 | 1.90 | 2025-09-15 | 10-Q |
| FY 2025 | 2024-04-30 | -1.80 | 2025-08-11 | 10-K |
| Q3 2025 | 2024-01-31 | -1.47 | 2025-03-17 | 10-Q |
| Q2 2025 | 2023-10-31 | -0.85 | 2024-12-13 | 10-Q |
| Q1 2025 | 2023-07-31 | -0.54 | 2024-09-17 | 10-Q |
| FY 2024 | 2023-04-30 | -0.22 | 2024-08-13 | 10-K |
| Q3 2024 | 2023-01-31 | -0.21 | 2024-03-18 | 10-Q |
| Q2 2024 | 2022-10-31 | -0.17 | 2023-12-15 | 10-Q |
| Q1 2024 | 2022-07-31 | -0.07 | 2023-09-18 | 10-Q |
| FY 2023 | 2022-04-30 | -0.27 | 2023-07-31 | 10-K |
| Q3 2023 | 2022-01-31 | -0.21 | 2023-03-16 | 10-Q |
| Q2 2022 | 2021-10-31 | -0.21 | 2022-12-14 | 10-Q |
| Q1 2023 | 2021-07-31 | -0.64 | 2022-09-14 | 10-Q |
| FY 2022 | 2021-04-30 | -2.45 | 2022-07-28 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.